Researchers unveil new approach to pandemic protection
An AI-designed vaccine has been tested in humans for the first time in what researchers describe as a major breakthrough in the fight against future pandemics.
Scientists at the University of Cambridge say they have developed a fundamentally new type of vaccine using artificial intelligence to create its key component. The vaccine is designed to provide protection against a broad family of coronaviruses, including current Covid variants as well as animal viruses that could potentially trigger future outbreaks.
Researchers believe the technology could eventually lead to vaccines capable of protecting against a much wider range of viruses than current approaches allow.
How the AI-designed vaccine works
Traditional vaccines are typically developed using a specific strain of a virus currently circulating in the population.
For this project, researchers gathered genetic data from multiple coronaviruses identified through surveillance programmes designed to monitor emerging viral threats.
Artificial intelligence analysed the genetic information and created what scientists describe as a “super-antigen” – a specially designed vaccine component intended to train the immune system to recognise and respond to an entire family of viruses, including future variants and previously unseen strains.
Antigens are the parts of vaccines that teach the immune system what to attack when an infection occurs.
Professor Jonathan Heeney of the University of Cambridge said this was the first time an antigen created entirely through artificial intelligence had been tested in people.
“The technology is surprising all of us,” he said. “It’s amazing what we can do with it for the good of humanity.”
He added that the goal is to develop vaccines capable of protecting against future outbreaks before they emerge.
“This is about making vaccines that protect us, not just from today’s viruses, but protect us from what can cause the next outbreak or disease,” Heeney said.
“This is a fundamental shift in how we prepare for pandemics.”
Early trials show promise
The first human trial involved 39 participants and was designed primarily to assess safety.
A second study involving around 200 people is now under way and is expected to provide a clearer picture of how effectively the AI-designed vaccine stimulates the immune system.
According to findings published in the Journal of Infection, the vaccine’s impact on immune responses was described as “modest”, although researchers and independent experts say the results remain highly encouraging given the early stage of development.
Professor Saul Faust of the University of Southampton, who participated in some of the trials, said the technology has significant potential.
“What’s really interesting is the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing,” he told the BBC.
Potential applications beyond Covid
Researchers are already applying the same technology to a range of other infectious diseases.
The Cambridge team is conducting animal studies on universal seasonal influenza vaccines that would not require annual reformulation. Work is also under way on a vaccine targeting H5N1 bird flu amid concerns the virus could eventually develop into a human pandemic.
Scientists are also investigating vaccines for viral haemorrhagic fevers, including Ebola.
The current Ebola outbreak in the Democratic Republic of the Congo is being driven by a strain for which no approved vaccine currently exists.
Researchers hope the AI-designed vaccine platform could significantly accelerate the development of protection against emerging health threats.
Experts see major role for AI in medicine
Independent experts believe artificial intelligence could transform vaccine development in the coming years.
Professor Andy Pollard, director of the Oxford Vaccine Group, said the findings were particularly encouraging because they suggest AI can generate immune responses that many scientists would not previously have predicted.
“It’s fascinating data and people wouldn’t have predicted they’d be able to generate these immune responses,” he told BBC News.
He noted that the ultimate test will be the results of larger human trials, as human immune systems are more complex than those of laboratory animals.
More broadly, Pollard described artificial intelligence as a potential “game changer” for vaccine research, arguing that AI tools could dramatically speed up vaccine development and help predict how the immune system will respond to new treatments.
A new era for vaccine development
The successful testing of an AI-designed vaccine marks a significant milestone in the growing role of artificial intelligence within medicine.
Professor Marian Knight, Scientific Director at the National Institute for Health and Care Research, described the trial as a pivotal step forward in the pursuit of broad and long-lasting viral protection.
UK Science Minister Lord Vallance also welcomed the results, describing them as another example of how scientific research and artificial intelligence can work together to develop new medical treatments.
With larger trials continuing and researchers expanding the technology to other diseases, scientists believe AI-designed vaccine platforms could eventually help countries respond faster to emerging health threats and strengthen global pandemic preparedness.
Source: BBC
Also read: GeSY healthcare quality faces its next big test
For more videos and updates, check out our YouTube channel
